Back to resultsInflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior (IBBBiS)
Primary Purpose
Suicide, Depression
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood samples
Hetero-questionnaires and auto-questionnaires
Magnetic Resonance Imaging (MRI)
Sponsored by
About this trial
This is an interventional other trial for Suicide focused on measuring suicide, depression
Eligibility Criteria
Common inclusion criteria: Aged between 18 and 55 years old, Affiliated to a French National Social Security System Able to understand the nature, purpose and methodology of the study Able to give written informed consent Specific inclusion criteria Suicide attempters: Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion) Subject with a recent history of proven suicide attempt (within the 8 days before inclusion) Subject with a history of maximum 2 previous lifetime proven SA Affective controls: Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion), Subject without any lifetime history suicidal behavior (proven, interrupted or aborted) Healthy controls: - Subject who have no current or past personal history of psychiatric disorders according to DSM5 criteria. Non inclusion criteria History of psychotic disorders Diagnostic of illicit substance / alcohol use disorder within the last 6 months Current inflammation-related symptoms including fever and infectious or inflammatory disease Severe symptomatic or unstable medical condition (e.g., unstable endocrine or cardiovascular disease) Medical disorders affecting CNS function (e.g., history of severe head trauma, epilepsy, tumor) Current use of specific medications known to affect the immune system, such as corticosteroids, non-steroid anti-inflammatory drugs, aspirin and statins Contraindication to MRI or impossibility to assess, or doubt about a contraindication to the MRI: metallic artificial heart valve, pacemaker, cerebrovascular clips ferromagnetic materials, metallic foreign body that can be mobilized, in particular cerebral or intraocular, prosthesis ferromagnetic, impossibility of absolute immobility in supine position, claustrophobia. Vaccination in the last month Law protected or deprived of liberty subject Pregnant and breastfeeding women BMI > 30 kg/m2 Having reached 6000€ annual compensation for participating to clinical trials Being in exclusion period for another study
Sites / Locations
- University hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Suicide attempters
Affective controls
Healthy controls
Arm Description
Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent );
Currently depressed patients without any lifetime history of suicide attempt
Participants with no lifetime history of psychiatric disorders
Outcomes
Primary Outcome Measures
Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions.
Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions.
Secondary Outcome Measures
Cytokines' concentration by multiplex ELISA (pg/ml)
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Cytokines' concentration by multiplex ELISA (pg/ml)
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Specific proteins measurement (pg/ml)
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
Specific proteins measurement (pg/ml)
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
FACS analysis on fresh blood
Determination of the number of white cells
FACS analysis on fresh blood
Determination of the number of white cells
FACS analysis on fresh blood
Description of the phenotype of white cells
FACS analysis on fresh blood
Description of the phenotype of white cells
FACS analysis on fresh blood
Percentage of cellular inflammatory marker
FACS analysis on fresh blood
Percentage of cellular inflammatory marker
Extraction of small and long RNA
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
Extraction of small and long RNA
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
White matter microstructure analysis
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
White matter microstructure analysis
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
White matter microstructure analysis
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
White matter microstructure analysis
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
White matter microstructure analysis
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
White matter microstructure analysis
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
White matter microstructure analysis
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
White matter microstructure analysis
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
White matter microstructure analysis
Value of diffusion of the tissue (ADC) from different region based on regional atlases
White matter microstructure analysis
Value of diffusion of the tissue (ADC) from different region based on regional atlases
White matter microstructure analysis
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
White matter microstructure analysis
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Regional homogeneity
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Regional homogeneity
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Amplitude of low frequency fluctuations
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Amplitude of low frequency fluctuations
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Functional homotopy
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Functional homotopy
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Graph theory metrics
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Graph theory metrics
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the volume from cerebral anatomical atlas
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the volume from cerebral anatomical atlas
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the surface from cerebral anatomical atlas
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the surface from cerebral anatomical atlas
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the cortical thickness from cerebral anatomical atlas
Cerebral morphometric extraction (3DT1): automatic segmentation
Evaluation of the cortical thickness from cerebral anatomical atlas
Cerebral blood analysis
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
Cerebral blood analysis
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
Full Information
NCT ID
NCT06047613
First Posted
July 21, 2023
Last Updated
September 14, 2023
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT06047613
Brief Title
Inflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior
Acronym
IBBBiS
Official Title
Inflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
March 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Recent studies have revealed an association between history of suicide attempt and inflammatory markers in both the cerebrospinal fluid and the plasma. Post mortem studies have shown an increase in microglial activation in the brain tissue of suicide victims. However the relationship between peripheral and central inflammation in suicide is probably mediated by complex biological processes that are yet elucidated. An increase of blood S100B levels (biomarker of neurovascular damage; PMID 14530574) has been reported in adolescents with suicidal ideation vs. controls and independently of psychiatric disorder.
The investigators hypothesize that peripheral inflammation may alter the blood brain barrier, which normally acts as a filter to ensure proper neuronal functioning, in suicidal patients.
They propose to investigate peripheral inflammation, neurovascular permeability and miRNAs in suicidal behavior pathophysiology as biomarkers of suicidal behavior in depression
Detailed Description
150 participants will be enrolled, divided into 3 groups:
50 Suicide attempters, i.e. currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempts, including the most recent);
50 Affective controls, i.e. currently depressed patients without any lifetime history of suicide attempt;
50 Healthy controls (age- and gender-matched to patients' groups) with no lifetime history of psychiatric disorders.
The protocol includes two visits for patients (suicide attempters and affective controls) and only one visit (inclusion) for healthy controls.
The first visit is the inclusion visit (Day 0-Day 8). Day 0 is the date of the last suicide attempt for the suicide attempters group and the date of signature of the consent for the affective control and healthy control groups. All the visit exams will be performed within 8 days after Day 0.
The second visit takes place one month +/- one week after inclusion. At each visit, a clinical assessment will be performed to characterise psychopathology and suicidal characteristics. Blood samples will be obtained in order to measure inflammatory markers. An MRI will be performed on order to study white matter microstructure and brain functional connectivity networks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Suicide, Depression
Keywords
suicide, depression
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Suicide attempters
Arm Type
Experimental
Arm Description
Currently depressed patients with a suicide attempt within the 8 last days (with a maximal lifetime number of 3 previous suicide attempt including the most recent );
Arm Title
Affective controls
Arm Type
Active Comparator
Arm Description
Currently depressed patients without any lifetime history of suicide attempt
Arm Title
Healthy controls
Arm Type
Active Comparator
Arm Description
Participants with no lifetime history of psychiatric disorders
Intervention Type
Biological
Intervention Name(s)
Blood samples
Intervention Description
Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
Intervention Type
Other
Intervention Name(s)
Hetero-questionnaires and auto-questionnaires
Intervention Description
Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.
Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself.
Intervention Type
Other
Intervention Name(s)
Magnetic Resonance Imaging (MRI)
Intervention Description
MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
Primary Outcome Measure Information:
Title
Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions.
Time Frame
At inclusion
Title
Level of blood S100B assayed in the 3 groups, a marker of cerebral and vascular lesions.
Time Frame
At 1 month follow-up
Secondary Outcome Measure Information:
Title
Cytokines' concentration by multiplex ELISA (pg/ml)
Description
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Time Frame
At inclusion
Title
Cytokines' concentration by multiplex ELISA (pg/ml)
Description
C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL20, CCL22, CCL26, C-X-C motif chemokine ligand (CXCL)10, Interleukin (IL)-1α, IL 1ß, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23 p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL- 27, IL-31, interferon (IFN)-γ, Tumor Necrosis Factor ðTNFÞ α, TNF ß and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Time Frame
At 1 month follow-up
Title
Specific proteins measurement (pg/ml)
Description
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
Time Frame
At inclusion
Title
Specific proteins measurement (pg/ml)
Description
Specific proteins measurement (i.e. GFAP, NFL, UHC-L1, sGPR56, S100B, MBP and related proteins) using digital or classical ELISA or western blot
Time Frame
At 1 month follow-up
Title
FACS analysis on fresh blood
Description
Determination of the number of white cells
Time Frame
At inclusion
Title
FACS analysis on fresh blood
Description
Determination of the number of white cells
Time Frame
At 1 month follow-up
Title
FACS analysis on fresh blood
Description
Description of the phenotype of white cells
Time Frame
At inclusion
Title
FACS analysis on fresh blood
Description
Description of the phenotype of white cells
Time Frame
At 1 month follow-up
Title
FACS analysis on fresh blood
Description
Percentage of cellular inflammatory marker
Time Frame
At inclusion
Title
FACS analysis on fresh blood
Description
Percentage of cellular inflammatory marker
Time Frame
At 1 month follow-up
Title
Extraction of small and long RNA
Description
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
Time Frame
At inclusion
Title
Extraction of small and long RNA
Description
Use of RNA-seq, RT-qPCR and digital PCR to quantify RNA
Time Frame
At 1 month follow-up
Title
Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization
Description
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
Time Frame
At inclusion
Title
Test of the capacity of leukocytes isolated from patients to provoke vascular inflammation and BBB permeabilization
Description
These experiments will be performed using an in vitro model of vascular cell co-culture. The reactivity of leukocytes to pro-inflammatory challenges and cytokines will be tested.
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
The ihMT (ihMTR) and MT (MTR) ratios will be performed in the apparently normal white and gray matter regions from regional white matter and gray matter atlases
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
Value of the fraction of anisotropy (FA) along the skeleton of the Tract-based spatial statistics TBSS
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
Extraction by anatomical region of FA, mean, axial and radial diffusivity [FSL software)
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
Value of diffusion of blood water D* (pseudocoefficient =perfusive composante) from different region based on regional atlases
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
Value of diffusion of the tissue (ADC) from different region based on regional atlases
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
Value of diffusion of the tissue (ADC) from different region based on regional atlases
Time Frame
At 1 month follow-up
Title
White matter microstructure analysis
Description
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
Time Frame
At inclusion
Title
White matter microstructure analysis
Description
Value of fraction of perfusion fD* ( incoherent blood signal divided by total incoherent signal) from different region based on regional atlases
Time Frame
At 1 month follow-up
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Regional homogeneity
Time Frame
At inclusion
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Regional homogeneity
Time Frame
At 1 month follow-up
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Amplitude of low frequency fluctuations
Time Frame
At inclusion
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Amplitude of low frequency fluctuations
Time Frame
At 1 month follow-up
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Functional homotopy
Time Frame
At inclusion
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Functional homotopy
Time Frame
At 1 month follow-up
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Graph theory metrics
Time Frame
At inclusion
Title
Brain functional connectivity networks analysis : extraction of resting state functional connectivity metrics from functional atlas or by voxel
Description
Graph theory metrics
Time Frame
At 1 month follow-up
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the volume from cerebral anatomical atlas
Time Frame
At inclusion
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the volume from cerebral anatomical atlas
Time Frame
At 1 month follow-up
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the surface from cerebral anatomical atlas
Time Frame
At inclusion
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the surface from cerebral anatomical atlas
Time Frame
At 1 month follow-up
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the cortical thickness from cerebral anatomical atlas
Time Frame
At inclusion
Title
Cerebral morphometric extraction (3DT1): automatic segmentation
Description
Evaluation of the cortical thickness from cerebral anatomical atlas
Time Frame
At 1 month follow-up
Title
Cerebral blood analysis
Description
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
Time Frame
At inclusion
Title
Cerebral blood analysis
Description
Extraction of blood flow values from 3D PCASL acquisition from vascular atlas
Time Frame
At 1 month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Common inclusion criteria:
Aged between 18 and 55 years old,
Affiliated to a French National Social Security System
Able to understand the nature, purpose and methodology of the study
Able to give written informed consent
Specific inclusion criteria
Suicide attempters:
Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion)
Subject with a recent history of proven suicide attempt (within the 8 days before inclusion)
Subject with a history of maximum 2 previous lifetime proven SA
Affective controls:
Subject with a main psychiatric diagnosis of current major depressive episode according to DSM-5 criteria (the existence of psychiatric comorbidities is not a non-inclusion criterion),
Subject without any lifetime history suicidal behavior (proven, interrupted or aborted)
Healthy controls:
- Subject who have no current or past personal history of psychiatric disorders according to DSM5 criteria.
Non inclusion criteria
History of psychotic disorders
Diagnostic of illicit substance / alcohol use disorder within the last 6 months
Current inflammation-related symptoms including fever and infectious or inflammatory disease
Severe symptomatic or unstable medical condition (e.g., unstable endocrine or cardiovascular disease)
Medical disorders affecting CNS function (e.g., history of severe head trauma, epilepsy, tumor)
Current use of specific medications known to affect the immune system, such as corticosteroids, non-steroid anti-inflammatory drugs, aspirin and statins
Contraindication to MRI or impossibility to assess, or doubt about a contraindication to the MRI: metallic artificial heart valve, pacemaker, cerebrovascular clips ferromagnetic materials, metallic foreign body that can be mobilized, in particular cerebral or intraocular, prosthesis ferromagnetic, impossibility of absolute immobility in supine position, claustrophobia.
Vaccination in the last month
Law protected or deprived of liberty subject
Pregnant and breastfeeding women
BMI > 30 kg/m2
Having reached 6000€ annual compensation for participating to clinical trials
Being in exclusion period for another study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Philippe COURTET, MD PhD
Phone
+33 4 67 33 85 81
Email
p-courtet@chu-montpellier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Emilie OLIE, MD PhD
Phone
+33 4 67 33 85 81
Email
e-olie@chu-montpellier.fr
Facility Information:
Facility Name
University hospital
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica DALAUDIERE
Phone
+33499614569
Email
jessica.dalaudiere@chu-montpellier.fr
12. IPD Sharing Statement
Learn more about this trial
Inflammation and Blood Brain Barrier Integrity as Biomarkers of Suicidal Behavior
We'll reach out to this number within 24 hrs